Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,239 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B.
Yu R, Tan D, Ning Q, Niu J, Bai X, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J, Xie Q, Sun J. Yu R, et al. Among authors: sheng j. Hepatol Res. 2018 Feb;48(3):E213-E221. doi: 10.1111/hepr.12972. Epub 2017 Oct 4. Hepatol Res. 2018. PMID: 28834607
The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study.
Sun J, Xie Q, Tan D, Ning Q, Niu J, Bai X, Fan R, Chen S, Cheng J, Yu Y, Wang H, Xu M, Shi G, Wan M, Chen X, Tang H, Sheng J, Dou X, Shi J, Ren H, Wang M, Zhang H, Gao Z, Chen C, Ma H, Jia J, Hou J. Sun J, et al. Among authors: sheng j. Hepatology. 2014 Apr;59(4):1283-92. doi: 10.1002/hep.26885. Epub 2014 Feb 28. Hepatology. 2014. PMID: 24382690 Clinical Trial.
[Analysis of a randomized, double-blind, double-dummy, controlled, multicenter study confirmed the similar therapeutic efficacies of entecavir maleate and entecavir for treatment of HBeAg-positive chronic hepatitis B].
Xu JH, Yu YY, Si CW, Zeng Z, Li J, Mao Q, Zhang DZ, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J, Xu ZN. Xu JH, et al. Among authors: sheng jf. Zhonghua Gan Zang Bing Za Zhi. 2013 Dec;21(12):881-5. doi: 10.3760/cma.j.issn.1007-3418.2013.12.001. Zhonghua Gan Zang Bing Za Zhi. 2013. PMID: 24636286 Clinical Trial. Chinese.
Peginterferon alfa-2b in the treatment of Chinese patients with HBeAg-positive chronic hepatitis B: a randomized trial.
Cheng J, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Mohamed R, Guan R, Lee TH, Chang WH, Zhenfei H, Ye Z, Xu D. Cheng J, et al. Among authors: sheng j. J Clin Virol. 2014 Dec;61(4):509-16. doi: 10.1016/j.jcv.2014.08.008. Epub 2014 Aug 18. J Clin Virol. 2014. PMID: 25200354 Free article. Clinical Trial.
Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients.
Liang X, Cheng J, Sun Y, Chen X, Li T, Wang H, Jiang J, Chen X, Long H, Tang H, Yu Y, Sheng J, Chen S, Niu J, Ren H, Shi J, Dou X, Wan M, Jiang J, Xie Q, Shi G, Ning Q, Chen C, Tan D, Ma H, Sun J, Jia J, Zhuang H, Hou J. Liang X, et al. Among authors: sheng j. J Gastroenterol Hepatol. 2015 Apr;30(4):748-55. doi: 10.1111/jgh.12835. J Gastroenterol Hepatol. 2015. PMID: 25352300 Clinical Trial.
Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBeAg-positive chronic hepatitis B patients receiving peginterferon.
Hou FQ, Song LW, Yuan Q, Fang LL, Ge SX, Zhang J, Sheng JF, Xie DY, Shang J, Wu SH, Sun YT, Wei SF, Wang MR, Wan MB, Jia JD, Luo GH, Tang H, Li SC, Niu JQ, Zhou WD, Sun L, Xia NS, Wang GQ. Hou FQ, et al. Among authors: sheng jf. Theranostics. 2015 Jan 1;5(3):218-26. doi: 10.7150/thno.10636. eCollection 2015. Theranostics. 2015. PMID: 25553110 Free PMC article. Clinical Trial.
Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues.
Fan R, Sun J, Yuan Q, Xie Q, Bai X, Ning Q, Cheng J, Yu Y, Niu J, Shi G, Wang H, Tan D, Wan M, Chen S, Xu M, Chen X, Tang H, Sheng J, Lu F, Jia J, Zhuang H, Xia N, Hou J; Chronic Hepatitis B Study Consortium. Fan R, et al. Among authors: sheng j. Gut. 2016 Feb;65(2):313-20. doi: 10.1136/gutjnl-2014-308546. Epub 2015 Jan 13. Gut. 2016. PMID: 25586058 Free PMC article. Clinical Trial.
HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients.
Yang S, Xing H, Wang Y, Hou J, Luo D, Xie Q, Ning Q, Ren H, Ding H, Sheng J, Wei L, Chen S, Fan X, Huang W, Pan C, Gao Z, Zhang J, Zhou B, Chen G, Wan M, Tang H, Wang G, Yang Y, Xu D, Dong P, Wang Q, Wang J, Bognar FA, Xu D, Cheng J. Yang S, et al. Among authors: sheng j. Virol J. 2016 Oct 28;13(1):180. doi: 10.1186/s12985-016-0640-1. Virol J. 2016. PMID: 27793166 Free PMC article. Clinical Trial.
3,239 results